CTLA4 and Alzheimer disease: Administration of anti-CTLA-4 mAb significantly increased (non-AD; p = 0.007, AD; p = 0.017) the CD86 expression on MHC class IIhighFITC+ migratory DCs on day one after FITC sensitization in both non-AD and AD mice.